首頁 > 市場調查報告書 > 醫療設備

婦科治療

市場調查報告書

商品編碼

1542895

全球子宮肌瘤治療市場 - 2024-2031

Global Uterine Fibroids Treatment Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

子宮肌瘤治療市場規模

2023年，全球子宮肌瘤治療市場規模達13.6341億美元，預計2031年將達到27.3947億美元，2024-2031年預測期間複合年成長率為9.4%。

子宮肌瘤是女性子宮最常見的良性非癌性腫瘤，常見於生育期間。肌瘤只有在引起症狀時才需要治療，治療方案包括藥物治療和侵入性手術。子宮肌瘤治療市場有巨大的成長機會。全球子宮肌瘤治療市場主要是由於女性老年人口的增加、荷爾蒙失調的盛行率不斷上升以及生活方式的改變而導致患者人數不斷增加。

子宮肌瘤治療市場動態

全球子宮肌瘤治療市場的主要成長動力是個人疾病意識的提高、高效新技術的發展、全球政府活動的增加、子宮肌瘤發病率的激增以及人們生活方式的改變，以及育齡婦女人數不斷增加。

子宮肌瘤發生率的上升推動了全球市場的成長。

子宮肌瘤是女性最常見的骨盆腔腫瘤，在全球發生，盛行率為 21.4%。子宮肌瘤是女性最常見但尚未充分研究的疾病之一。國際婦產科聯合會 2020 年資料表明，這些腫瘤（俗稱子宮肌瘤）主要影響育齡期女性，高達 70% 的白人女性和超過 80% 的非洲裔女性在一生中被診斷出患有這種腫瘤。這種疾病對全球醫療保健服務和成本產生深遠影響。雖然大多數患有子宮肌瘤的女性沒有症狀，但大約 30% 的女性會出現嚴重症狀，包括異常子宮出血、貧血、骨盆疼痛和壓力、背痛、頻尿、便秘或不孕，需要介入。在美國，每年約有 650 萬名女性因肌瘤尋求治療，近 1/3 的就業患者 (28%) 報告因肌瘤症狀而缺勤。

對治療方案的認知不足將阻礙市場的成長。

然而，社區和醫學界對肌瘤的關注有限，這意味著高風險女性無法獲得所需的有關疾病的知識。《女性健康期刊》2020 年的研究發現，只有 49% 的高風險女性有症狀，但並未臨床診斷為子宮肌瘤。症狀出現後，大多數女性 (60%) 試圖自行控制症狀或等待症狀是否消失 (50%)。即使女性被診斷出子宮肌瘤，她們的治療選擇也是有限的，並且會影響她們的生育能力。女性可以服用非處方非類固醇抗發炎藥物 (NSAID) 和對乙醯氨基酚來緩解與子宮肌瘤相關的疼痛，但這些只是暫時緩解骨盆疼痛。某些形式的節育措施可以幫助緩解大量出血，但並不適用於所有女性，也不是嘗試懷孕的女性的選擇。

COVID-19 對子宮肌瘤治療市場的影響分析

COVID-19大流行對婦科手術產生了重大影響。美國外科醫師學會建議在2020 年3 月之前推遲所有不必要的侵入性手術。研究論文，2019 年共完成了1,545 例婦科手術，與 2020 年的 942 例相比，下降了 39.0%。對全球市場產生負面影響。

子宮肌瘤治療市場細分分析

在預測期內（2024-2031年），手術方法領域預計將更能掌握子宮肌瘤治療市場。

2021 年，手術方法細分市場佔據最大市場佔有率。然而，醫生通常會建議那些肌瘤引起中度或重度症狀（如疼痛或大量出血）的女性接受手術。治療子宮肌瘤的手術可以包括保留器官或部分或全部器官切除。子宮肌瘤的手術治療採用三種方法（腹部、腹腔鏡、陰道）或三種方法的組合。進行幾種類型的外科手術來治療子宮肌瘤。其中包括子宮內膜消融、MRI 導引手術、子宮切除術、子宮肌瘤切除術、子宮動脈栓塞術 (UAE) 和射頻消融術等。其中，子宮切除術在2021年佔據了最大的市場。

子宮肌瘤治療市場地域佔有率

預計北美將主導全球子宮肌瘤治療市場。

北美在子宮肌瘤治療市場上佔據主導地位，預計在預測期內（2022-2029年）將呈現類似的趨勢。由於其成熟的醫療保健行業，特別是在美國和加拿大，人們的意識不斷提高，並且易於獲得先進技術。荷爾蒙失調患者數量的增加和子宮癌盛行率的增加是該區域子宮肌瘤治療市場的關鍵成長促進因素。例如，在美國，女性 35 歲時子宮肌瘤的盛行率為 60%，到 50 歲時增加至 80% 以上。

此外，開放式手術的微創有效替代方案的出現、技術進步和頻繁的治療類型創新，加上監管批准的增加和有利的報銷政策，預計將推動該地區市場的成長。

子宮肌瘤治療公司及競爭格局

子宮肌瘤治療市場是本地和全球公司競爭適度的市場。推動市場成長的一些主要參與者包括波士頓科學公司（Minerva Surgical）、Cooper Surgical, Inc.、奧林巴斯公司、Acessa Health（Halt Medical, Inc.）、Gynesonics、Conmed Corporation、AbbVie Inc.。、Karl Storz、Richard Wolf GmbH、LiNA Medical USA、Blue Endo 等。主要參與者正在採取多種成長策略，例如治療類型的推出、收購和合作，為全球市場的成長做出貢獻。例如，2020 年 5 月 12 日，Minerva Surgical, Inc 從 Boston Scientific 收購了以下子宮內健康治療類型：Symphion 組織移除系統； Resectr 組織切除裝置；和 Genesys HTA 系統。

波士頓科學公司

概述：

該公司成立於1979年，總部位於美國。波士頓科學公司開發、製造和銷售微創醫療設備。該公司的治療類型用於介入性心臟病學、心律管理、周邊干預、電生理學、神經血管干預、內視鏡檢查、泌尿科、婦科和神經調節。

治療類型組合：

Symphion 組織切除系統：一體化 Symphion 系統旨在改變您切除子宮組織的方式。它將突破性的液體管理、直接子宮內壓力監測和無刀切除完美結合在一起。

全球子宮肌瘤治療報告將提供約 40 多個市場資料表、45 多個數字和 200 多個（約）頁數。

Uterine fibroids are a woman's uterus's most commonly benign, non-cancerous tumors, often seen during childbearing. Fibroids are only treated if they cause symptoms, and treatment options range from medications to invasive surgery. The uterine fibroids treatment market has significant opportunities to grow. The global uterine fibroids treatment market is primarily driven by an increasing patient pool owing to the increasing female geriatric population, the growing prevalence of hormonal disorders, and changing lifestyles.

Uterine Fibroids Treatment Market Dynamics

Major growth drivers of the uterine fibroids treatment market over the globe are an increase in consciousness among individuals about diseases, growth of efficient and new technology, rising government activities over the globe, a surge in occurrence of uterine fibroids, and changed people's lifestyle, and increasing number of women of reproductive age.

The rising incidences of uterine fibroids drive global market growth.

Uterine fibroids are women's most common pelvic tumors, occurring globally, with a prevalence of 21.4%. Uterine leiomyomas are among women's most common yet understudied diseases. The International Federation of Gynecology and Obstetrics 2020 data states that these tumors, commonly known as fibroids, affect women mainly during their reproductive years and are diagnosed in up to 70% of white women and more than 80% of women of African ancestry during their lifetime. This disease has a profound impact on healthcare delivery and costs worldwide. Though most women with fibroids are asymptomatic, approximately 30% will present with severe symptoms, including abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, urinary frequency, constipation, or infertility, and will require intervention. Every year in the United States, approximately 6.5 million women seek treatment for fibroids, and nearly 1/3 of employed patients (28%) report missing work days due to fibroid symptoms.

The low awareness of treatment options will hamper the growth of the market.

However, limited attention to fibroids in the community and the medical society means that at-risk women do not have access to the knowledge they need regarding the disease. The 2020 study in the Journal of Women's Health uncovered that only 49% of at-risk women with manifestations suggest fibroids but not a clinical diagnosis of uterine fibroids. Following the onset of their symptoms, most of these women (60%) tried to manage symptoms themselves or waited to see if the symptoms went away (50%). Even when women receive a fibroid diagnosis, their treatment options are limited and affect their fertility. Women can take over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen to alleviate pain associated with uterine fibroids, but these are just momentary fixes for pelvic pain. Some forms of birth control can help alleviate heavy bleeding but don't work for all women and are not an option for women trying to get pregnant.

COVID-19 Impact Analysis on Uterine Fibroids Treatment Market

The COVID-19 pandemic had a significant impact on gynecological surgery. The American College of Surgeons has recommended delaying all unnecessary invasive surgery by March 2020. According to a December 2021 research paper titled analysis of response and effects impact of COVID-19 on gynaecological surgery in major university hospitals, 1,545 gynecologic cases were done in 2019, compared to 942 cases in 2020, suggesting a 39.0% decline. Negatively impacting the global market.

Uterine Fibroids Treatment Market Segmentation Analysis

The surgical methods segment is expected to have a greater grasp of the uterine fibroids treatment market during the forecast period (2024-2031).

The surgical methods segment accounts for the largest market share in 2021. Medications can help if the symptoms are mild. However, doctors usually recommend procedures for women whose fibroids cause moderate or severe symptoms, like pain or heavy bleeding. Surgery to treat uterine fibroids can include organ preservation or involve partial or total organ removal. Three approaches (abdominal, laparoscopic, vaginal) or a combination of the three are used for the surgical treatment of uterine fibroids. Several types of surgical procedures are performed for the treatment of uterine fibroids. Dome of them includes endometrial Ablation, MRI Guided Procedures, Hysterectomy, Myomectomy, Uterine Artery Embolization (UAE), and Radiofrequency Ablation, among others. Among these, Hysterectomy accounted for the largest market share in 2021.

Uterine Fibroids Treatment Market Geographical Share

North America is expected to dominate the global uterine fibroids treatment market.

North America dominates the market for uterine fibroids treatment and is expected to show a similar trend over the forecast period (2022-2029). Owing to its established healthcare industry, particularly in the U.S. and Canada, increased awareness, and easy accessibility to advanced technologies. The increased patient pool undergoing hormonal disorders and increasing prevalence of uterine cancer is the key growth driving factor for this regional uterine fibroid treatment market. For instance, in the USA, the prevalence of uterine fibroids was 60% at age 35, which increased to more than 80% by 50 years among women.

Moreover, the advent of minimally invasive and effective alternatives to open surgeries, technological advancements, and frequent Treatment Type innovations coupled with an increase in regulatory approvals and favorable reimbursement policies are expected to boost the market's growth in the region.

Uterine Fibroids Treatment Companies and Competitive Landscape

The uterine fibroids treatment market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Boston Scientific Corporation (Minerva Surgical), Cooper Surgical, Inc., Olympus Corporation, Acessa Health (Halt Medical, Inc.), Gynesonics, Conmed Corporation, AbbVie Inc., Medtronic, Karl Storz, Richard Wolf GmbH, LiNA Medical USA, Blue Endo among others. The major players are adopting several growth strategies, such as Treatment Type launches, acquisitions, and collaborations, contributing to the global market growth. For instance, in May 12, 2020, Minerva Surgical, Inc, acquired the following Intrauterine Health Treatment Types from Boston Scientific: the Symphion Tissue Removal System; the Resectr Tissue Resection Device; and the Genesys HTA System.

Boston Scientific Corporation

Overview:

The company was founded in 1979. It has headquarters in the United States. Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company's Treatment Types are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology, and neuromodulation.

Treatment Type Portfolio:

Symphion Tissue Removal System: The all-in-one Symphion System is designed to transform how you remove uterine tissue. It unites breakthrough fluid management, direct intrauterine pressure monitoring, and bladeless resection to work together perfectly.

The global uterine fibroids treatment report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Incidences of Uterine Fibroids
  - 4.1.1.2. Increasing Technological Advancements
- 4.1.2. Restraints
  - 4.1.2.1. Complications Associated with Surgical Treatments
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Epidemiology
5.5. Pricing Analysis
5.6. Comparative analysis

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Treatment Type

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
- 7.1.2. Market Attractiveness Index, By Treatment Type Segment
7.2. Non-hormonal Treatment: Non-steroidal Anti-inflammatory Agents (NSAIDs)
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Hormonal Treatment
- 7.3.1. Oral contraceptives
- 7.3.2. Progestins/Antiprogestins
- 7.3.3. GnRH Agonists
7.4. Surgical Methods
- 7.4.1. Endometrial Ablation
- 7.4.2. MRI Guided Procedures
- 7.4.3. Hysterectomy
- 7.4.4. Myomectomy
- 7.4.5. Uterine Artery Embolization
- 7.4.6. Radiofrequency Ablation

8. By Type

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
- 8.1.2. Market Attractiveness Index, By Type Segment
8.2. Submucosal
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Subserosal
8.4. Intramural
8.5. Pedunculated

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
- 9.1.2. Market Attractiveness Index, By End User Segment
9.2. Hospitals And Clinics
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. ASCs
9.4. Wound Care Centers
9.5. Other

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. The U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking

12. Company Profiles

12.1. Boston Scientific Corporation (Minerva Surgical)
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
12.2. Cooper Surgical, Inc.
12.3. Olympus Corporation
12.4. Acessa Health (Halt Medical, Inc.)
12.5. Gynesonics
12.6. Conmed Corporation
12.7. AbbVie Inc.
12.8. Medtronic
12.9. Karl Storz
12.10. Richard Wolf GmbH
12.11. LiNA Medical USA
12.12. Blue Endo(*LIST NOT EXHAUSTIVE)